Substituting blood-based biomarkers for imaging measures in Alzheimer’s disease studies: implications for sample size and bias
Authors:
- Sarah F AckleySASarah F Ackley
- Renaud La JoieRJRenaud La Joie
- Michelle CauncaMCMichelle Caunca
- Paul K CranePCPaul K Crane
- Eleanor Hayes-LarsonEHEleanor Hayes-Larson
- For The Alzheimer’S Disease Neuroimaging InitiativeFIFor The Alzheimer’S Disease Neuroimaging Initiative
Open Access
- 15 March 2026
- journal article
- Published by Oxford University Press (OUP) in The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences
- Vol. 81 (5)
Abstract
Background: Blood-based biomarkers for Alzheimer’s disease (AD) pathology are appealing options in large population-based studies due to their low cost, minimal invasiveness, and feasibility of collection in non-clinical settings. Despite these benefits, blood-based biomarkers have lower test-retest reliability than neuroimaging measures like amyloid positron emission tomography (amyloid-PET) Centiloids; trade-offs in power and bias remain unexplored. Methods: We use data from Alzheimer’s Disease Neuroimaging Initiative (ADNI) and the Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease (A4) studies, which include both amyloid-PET and blood-based measures, to assess differences in statistical power, required sample size, and bias when replacing a neuroimaging measure with a blood-based measure. We use simulations parameterized based on these studies to show potential implications of using plasma p-tau 181 or p-tau 217, blood-based AD biomarkers, in place of Centiloids from amyloid-PET, when the biomarker is either the exposure or the outcome in an analysis of interest. Results: We demonstrated that substituting amyloid-PET Centiloids with a blood-based measure of p-tau can substantially reduce power, requiring 1.5-6.5 times the sample size to achieve 80% power compared to amyloid-PET. In addition, using a blood-based biomarker as the exposure can introduce significant regression dilution bias, attenuating estimated associations. Conclusions: While blood-based biomarkers are lower cost and easier to collect than neuroimaging measures, their use as proxies for AD pathology may introduce substantial methodological challenges, depending on the p-tau isoform. Consideration of the sample sizes they necessitate and their potential for bias is critical for the design and interpretation of studies employing these biomarkers.Keywords
Funding Information
- National Institute on Aging Grants (R00AG073454)
- National Institute on Aging Grants (R01AG082730)
- National Institute on Aging Grants (R00AG075317)
- National Institute on Aging Grants (R13AG064971)
- National Institute on Aging Grants (R01AG072681)
- National Institutes of Health
This publication has 50 references indexed in Scilit:
- Complementary utility of plasma biomarkers and Aβ‐PET for diagnosis, risk‐stratification, and treatment monitoring in Alzheimer's diseaseAlzheimer's & Dementia, 2025
- Body mass index and blood volume influence plasma biomarkers and positron emission tomography classification in preclinical Alzheimer's diseaseAlzheimer's & Dementia, 2025
- Chronic stress, social support, and Alzheimer's blood‐based biomarkers in the HABS‐HD studyAlzheimer's & Dementia, 2025
- Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association WorkgroupAlzheimer's & Dementia, 2024
- Biomarkers of Alzheimer's disease and neurodegeneration in dried blood spots—A new collection method for remote settingsAlzheimer's & Dementia, 2024
- Comparison of plasma biomarkers and amyloid PET for predicting memory decline in cognitively unimpaired individualsAlzheimer's & Dementia, 2024
- Association of Phosphorylated Tau Biomarkers With Amyloid Positron Emission Tomography vs Tau Positron Emission TomographyJAMA Neurology, 2023
- Using Alzheimer's disease blood tests to accelerate clinical trial enrollmentAlzheimer's & Dementia, 2022
- What the Aducanumab Approval Reveals About Alzheimer Disease ResearchJAMA Neurology, 2021
- Estimating sample size for epidemiologic studies: the impact of ignoring exposure measurement uncertaintyStatistics in Medicine, 1998